Collaboration Based on Ground-breaking Co-Invention with Tufts University School of Medicine Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has
Avacta Group plc (AIM:AVCT) Avacta and OncoSec to Collaborate
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they
Avacta Plc (AIM:AVCT) Drug Development Partnership with Glythera
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug
ShareSoc Company Seminar, Doubletree Hilton Hotel, Manchester 11.07.2017 (CMCL & AVCT)
After Monday’s excursion to GMCC to see NEX Exchange and Invesdor amongst others, Tuesday saw me take another short drive into Manchester to attend the ‘ShareSoc Manchester Growth Company Seminar’
